J. Pinski

发表

Luteinizing hormone‐releasing hormone antagonist Cetrorelix (SB‐75) and bombesin antagonist RC‐3940‐II inhibit the growth of androgen‐independent PC‐3 prostate cancer in nude mice

A. Schally, K. Groot, K. Szepesházi, 1997, The Prostate.

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.

A. Schally, K. Groot, A. Jungwirth, 1997, British Journal of Cancer.

Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.

A. Schally, K. Groot, K. Szepesházi, 1994, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.

A. Schally, K. Groot, Z. Rékási, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Inhibitory effect of bombesin/gastrin‐releasing peptide antagonist RC‐3095 and luteinizing hormone—releasing hormone antagonist SB‐75 on the growth of MCF‐7 MIII human breast cancer xenografts in athymic nude mice

A. Schally, K. Groot, K. Szepesházi, 1994, Cancer.

Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.

A. Schally, K. Groot, K. Szepesházi, 1994, British Journal of Cancer.

Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.

A. Schally, S. Radulović, T. Yano, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.

A. Schally, K. Groot, K. Szepesházi, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486.

A. Schally, J. Wittliff, G. Halmos, 1993, The Journal of clinical endocrinology and metabolism.

Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice.

A. Schally, G. Halmos, J. Pinski, 1993, Cancer letters.

Somatostatin receptor expression in lung cancer.

K. O'Byrne, A. Schally, K. Groot, 1994, European journal of cancer.

Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer.

A. Schally, B. Szoke, G. Halmos, 1994, Cancer letters.

Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma.

A. Schally, K. Groot, A. Jungwirth, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Development of a radioimmunoassay for some agonists of growth hormone-releasing hormone.

A. Schally, K. Groot, V. Csernus, 2009, International journal of peptide and protein research.

Comparison of GH-stimulation by GH-RH(1-29)NH2 and an agmatine29 GH-RH analog, after intravenous, subcutaneous and intranasal administration and after pulmonary inhalation in rats.

A. Schally, K. Groot, T. Yano, 2009, International journal of peptide and protein research.

Somatostatin analog RC‐160 inhibits the growth of human osteosarcomas in nude mice

A. Schally, K. Groot, K. Szepesházi, 1996, International journal of cancer.

Inhibition of growth of MKN45 human gastric‐carcinoma xenografts in nude mice by treatment with bombesin/gastrin‐releasing‐peptide antagonist (RC‐3095) and somatostatin analogue RC‐160

A. Schally, K. Szepesházi, T. Yano, 1994, International journal of cancer.

Effect of somatostatin analog RC‐160 and bombesin/gastrin releasing peptide antagonist RC‐3095 on growth of PC‐3 human prostate‐cancer xenografts in nude mice

A. Schally, K. Szepesházi, G. Halmos, 1993, International journal of cancer.

Effect of chronic administration of a new potent agonist of GH-RH(1–29)NH2 on linear growth and GH responsiveness in rats

A. Schally, K. Groot, A. Jungwirth, 1996, Regulatory Peptides.

Biological Activity and Receptor Binding Characteristics to Various Human Tumors of Acetylated Somatostatin Analogs

A. Schally, S. Radulović, T. Yano, 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines.

A. Schally, K. Groot, T. Yano, 1992, Cancer research.

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.

A. Schally, K. Groot, K. Szepesházi, 1997, European journal of cancer.

Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.

A. Schally, K. Groot, K. Szepesházi, 1994, Cancer research.

Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi.

A. Schally, K. Groot, S. Radulović, 2009, International journal of peptide and protein research.

Inhibition of the growth of caki‐I human renal adenocarcinoma in Vivo by luteinizing hormone‐releasing hormone antagonist cetrorelix, somatostatin analog RC‐160, and bombesin antagonist RC‐3940‐II

A. Schally, K. Groot, K. Szepesházi, 1998, Cancer.

Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi

A. Schally, S. Radulović, A. Nagy, 1992, Peptides.

Inhibition of passive anaphylaxis induced in the rat hind paw and peritoneal cavity by N-(2-oxo-3,5,7-cycloheptatrien-1-yl)-aminooxoacetic acid ethyl ester (AY-25,674).

J. Pinski, J. Klicius, P. Martel, 1978, Canadian journal of physiology and pharmacology.

Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.

A. Schally, K. Groot, M. Vadillo-Buenfil, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.

A. Schally, K. Groot, A. Jungwirth, 1996, Endocrinology.

High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration

A. Schally, S. Radulović, T. Yano, 1992, Regulatory Peptides.

Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH).

A. Schally, K. Groot, A. Jungwirth, 1996, International journal of oncology.

Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone.

A. Schally, K. Groot, K. Szepesházi, 1995, Journal of the National Cancer Institute.

Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH

R. Clarke, A. Schally, K. Groot, 1992, Breast Cancer Research and Treatment.

Chapter 73 – LHRH Analogs

A. Schally, J. Engel, N. Block, 2013 .

Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix (SB-75).

A. Schally, K. Groot, K. Szepesházi, 1993, Journal of andrology.

Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75).

A. Schally, K. Groot, G. Srkalović, 2009, International journal of peptide and protein research.

Blockade of the LH response induced by the agonist D‐Trp‐6‐LHRH in rats by a highly potent LH‐RH antagonist SB‐75

A. Schally, T. Yano, J. Pinski, 1992, The Prostate.

Effect of chlorpromazine on the disposition and excretion of amphetamine in the rat.

L. Borella, J. Pinski, F. Herr, 1970, Research communications in chemical pathology and pharmacology.

Inhibition of growth of experimental prostate cancer in rats by LH‐RH analogs linked to cytotoxic radicals

A. Schally, K. Groot, K. Szepesházi, 1993, The Prostate.

Terminology for luteinizing hormone-releasing hormone antagonists.

A. Schally, G. Halmos, J. Pinski, 1995, Fertility and sterility.

Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats.

A. Schally, K. Groot, T. Yano, 2009, International journal of peptide and protein research.

Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats

A. Schally, K. Groot, T. Yano, 1992, Peptides.

Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone.

A. Schally, K. Groot, J. Horváth, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.

A. Juhász, G. Srkalović, Z. Rékási, 1992, Proceedings of the National Academy of Sciences of the United States of America.

AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors

A. Schally, J. Pinski, G. Emons, 2012, Expert opinion on investigational drugs.

Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors.

A. Schally, G. Emons, J. Engel, 2011, Current drug delivery.

Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.

A. Schally, K. Groot, H. Reile, 1994, Cancer research.

Antagonists of bombesin/gastrin‐releasing peptide as adjuncts to agonists of luteinizing hormone–releasing hormone in the treatment of experimental prostate cancer

A. Schally, K. Szepesházi, G. Halmos, 1993, Cancer.

Inhibitory effects of analogs of luteinizing hormone‐releasing hormone on the growth of the androgen‐independent dunning R‐3327‐AT‐1 rat prostate cancer

A. Schally, K. Groot, G. Halmos, 1994, International journal of cancer.

Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin.

A. Schally, K. Groot, K. Szepesházi, 1997, International journal of oncology.

Effect of microcapsules of luteinizing hormone‐releasing hormone antagonist SB‐75 and somatostatin analog RC‐160 on endocrine status and tumor growth in the dunning R‐3327H rat prostate cancer model

A. Schally, K. Groot, K. Szepesházi, 1992, The Prostate.

Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.

A. Schally, K. Groot, K. Szepesházi, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats.

A. Schally, K. Groot, S. Radulović, 1992, The American journal of physiology.

Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.

A. Schally, K. Groot, H. Reile, 1994, Cancer research.

Somatostatin receptor expression in lung cancer.

K. Groot, K. Szepesházi, D. Carney, 1994, European journal of cancer.